{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"69","upperLimit":"100","value":"100"},{"groupId":"OG002","lowerLimit":"67","upperLimit":"100","value":"100"},{"groupId":"OG003","lowerLimit":"88","upperLimit":"100","value":"100"}]}],"title":"Combined median of CD3 at days (24, 56, 80, 180, 365, 730)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"100","upperLimit":"100","value":"100"},{"groupId":"OG002","lowerLimit":"91","upperLimit":"100","value":"100"},{"groupId":"OG003","lowerLimit":"100","upperLimit":"100","value":"100"}]}],"title":"Combined median of CD14 at days (24, 56, 80, 180, 365, 730)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"98","upperLimit":"100","value":"100"},{"groupId":"OG002","lowerLimit":"50","upperLimit":"100","value":"100"},{"groupId":"OG003","lowerLimit":"91","upperLimit":"100","value":"100"}]}],"title":"Combined median of CD33 at days (24, 56, 80, 180, 365, 730)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"100","upperLimit":"100","value":"100"},{"groupId":"OG002","lowerLimit":"60","upperLimit":"100","value":"100"},{"groupId":"OG003","lowerLimit":"90","upperLimit":"100","value":"100"}]}],"title":"Combined median of CD56 at days (24, 56, 80, 180, 365, 730)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"72"},{"groupId":"OG003","value":"10"}],"units":"Participants"}],"description":"Peripheral blood chimerism studies (sorted for CD3, CD14, CD33, CD56 cells) were collected for all UCBT recipients for days 28, 56, 80, 365, and 730 post-transplant. The combined median of the percent donor, along with full range, is captured to show change in level of chimerism at multiple time points up to 2 years post-transplant. Monitoring will take place separately for the single and double UCBT cohorts.","dispersionType":"Full Range","groups":[{"description":"Patients receive myeloablative conditioning comprising fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo high-dose TBI BID on days -4 to -1. Patients then undergo single-unit UCBT on day 0.\n\nFludarabine: Given IV Cyclophosphamide: Given IV Total-Body Irradiation: Undergo high-dose TBI Umbilical Cord Blood Transplantation: Undergo UCBT\n\nPatients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred \\> day 30) after engraftment if there continues to be no evidence of acute GVHD.\n\nCyclosporine: Given IV and PO Mycophenolate Mofetil: Given IV and PO Laboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Regimen A: High-dose TBI + Fludarabine + Cyclophosphamide; Single-cord Transplant"},{"description":"Patients receive myeloablative conditioning comprising fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 2-4 hours on days -5 and -4, and middle-intensity TBI QD on days -2 and -1. Patients then undergo single-unit UCBT on day 0.\n\nFludarabine: Given IV Cyclophosphamide: Given IV Thiotepa: Given IV Total-Body Irradiation: Undergo moderate-intensity TBI Umbilical Cord Blood Transplantation: Undergo UCBT\n\nPatients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred \\> day 30) after engraftment if there continues to be no evidence of acute GVHD.\n\nCyclosporine: Given IV and PO Mycophenolate Mofetil: Given IV and PO Laboratory Biomarker Analysis: Correlative studies","id":"OG001","title":"Regimen B: Middle-intensity TBI + Fludarabine + Cyclophosphamide + Thiotepa; Single-cord Transplant"},{"description":"Patients receive myeloablative conditioning comprising fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo high-dose TBI BID on days -4 to -1. Patients then undergo double-unit UCBT on day 0.\n\nFludarabine: Given IV Cyclophosphamide: Given IV Total-Body Irradiation: Undergo high-dose TBI Umbilical Cord Blood Transplantation: Undergo UCBT\n\nPatients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred \\> day 30) after engraftment if there continues to be no evidence of acute GVHD.\n\nCyclosporine: Given IV and PO Mycophenolate Mofetil: Given IV and PO Laboratory Biomarker Analysis: Correlative studies","id":"OG002","title":"Regimen A: High-dose TBI + Fludarabine + Cyclophosphamide; Double-cord Transplant"},{"description":"Patients receive myeloablative conditioning comprising fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 2-4 hours on days -5 and -4, and middle-intensity TBI QD on days -2 and -1. Patients then undergo double-unit UCBT on day 0.\n\nFludarabine: Given IV Cyclophosphamide: Given IV Thiotepa: Given IV Total-Body Irradiation: Undergo moderate-intensity TBI Umbilical Cord Blood Transplantation: Undergo UCBT\n\nPatients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred \\> day 30) after engraftment if there continues to be no evidence of acute GVHD.\n\nCyclosporine: Given IV and PO Mycophenolate Mofetil: Given IV and PO Laboratory Biomarker Analysis: Correlative studies","id":"OG003","title":"Regimen B: Middle-intensity TBI + Fludarabine + Cyclophosphamide + Thiotepa; Double-cord Transplant"}],"paramType":"MEDIAN","populationDescription":"Participants who received UCBT on study with chimerism data available within window as specified in protocol.","reportingStatus":"POSTED","timeFrame":"Baseline up to 2 years post-transplant","title":"Change in Level of Chimerism at Multiple Time Points","type":"SECONDARY","unitOfMeasure":"percentage chimerism (%)"}